Investors weren’t banking on FDA approval of Portola Pharmaceuticals (NASDAQ: PTLA) first commercial drug, Bevyxxa, so when regulators issued a green light last month, it caused the company’s shares to surge 54% higher, according to S&P Global Marke
Investors weren’t banking on FDA approval of Portola Pharmaceuticals (NASDAQ: PTLA) first commercial drug, Bevyxxa, so when regulators issued a green light last month, it caused the company’s shares to surge 54% higher, according to S&P Global Marke